What is it about?

We studied the risk of death among Medicare beneficiaries with Parkinson’s Disease receiving two types of medication for psychosis, pimavanserin or atypical (second generation) antipsychotics. Over the first six months, the risk of death was 35% lower for patients who received pimavanserin compared to patients who received atypical antipsychotics. The lower risk of death was observed only for patients not living in nursing homes and was not observed after 6 months of treatment. The major limitation of our study was that it was not a randomized, controlled trial; also, we did not assess the safety of pimavanserin versus no medication treatment of psychosis.

Featured Image

Read the Original

This page is a summary of: Mortality Among Parkinson’s Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries, American Journal of Psychiatry, August 2022, American Psychiatric Association, DOI: 10.1176/appi.ajp.21090876.
You can read the full text:

Read

Contributors

The following have contributed to this page